The identification of new active agents is essential if we are to alter the current survival rates for patients with squamous cell carcinoma of the head and neck. Paclitaxel (TAXOL®) is a taxane derivative isolated from the bark of the western yew Taxus brevifolia. The drug has a novel mechanism of action promoting microtubule assembly and stabilizing the tubulin polymers. One phase II trial of paclitaxel (250 mg/m2) in head and neck cancer patients is in progress. The preliminary results of this Eastern Cooperative Oncology Group trial indicate that paclitaxel has activity against this tumor: two complete and seven partial responses in 19 patients assessable for response. Grades 3 and 4 neutropenia and grades 1 and 2 neuropathy were frequently observed toxicities. Future directions include a National Cancer Institute-sponsored confirmatory trial using the same dose and schedule of paclitaxel. The European Organization for Research and Treatment of Cancer plans a randomized comparison of paclitaxel versus weekly methotrexate. The Eastern Cooperative Oncology Group will pursue testing of paclitaxel at two different doses (200 and 135 mg/m2) in combination with cisplatin in patients with advanced head and neck cancer.
|Original language||English (US)|
|Number of pages||5|
|Journal||Seminars in oncology|
|Issue number||4 SUPPL. 3|
|State||Published - Aug 23 1993|
ASJC Scopus subject areas